Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05825560

Opioid-free Analgesia in Intensive Care Unit

Opioid-free Analgesia in Intensive Care Unit: a Prospective, Monocentric, Randomized, Double Blind, Feasability Clinical Trial

Status
Recruiting
Phase
Phase 4
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Centre Hospitalier Universitaire de Nīmes · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

ICU patients experience moderate to severe pain. Studies and guidelines point out the benefits of multimodal analgesia on pain control, opioid spare and on lowering its adverse effects. However, no recommendation about drugs or protocol has been formulated. In our study, investigators studied the feasibility and the impact on Remifentanil spare of a standardized protocol using multimodal analgesia (Paracetamol, Nefopam, Tramadol, Ketamine, Remifentanil) compared to the standard-of-care strategy using Paracetamol and Remifentanil. The investigators conducted a prospective, ''proof of concept'', randomized, double-blind, parallel group, placebo-controlled trial. The investigators studied multimodal analgesia versus standard-of-care in ICU patients requiring sedation-analgesia for invasive mechanical ventilation.The investigators hypothesized that Remifentanil consumption decrease by 15% with the use of a standardized multimodal analgesia strategy

Detailed description

ICU patients requiring sedation-analgesia for mechanical ventilation for at least 48 hours are randomized in 2 parallel groups : control arm using ''standard of care'' analgesia (Paracetamol and Remifentanil), and interventional arm using multimodal analgesia at different level according to pain accessed by BPS (Step 1 : Paracetamol, Nefopam, Tramadol, Step 2 : Ketamine, Step 3 : Remifentanil). Sedation drugs are standard of care (Propofol and Midazolam if Propofol isn't enough) to obtain prescribed sedation accessed by RASS. Double-bling is kept for 72 hours until the primary outcome is obtained. The investigators hypothesize a 15% reduction of Remifentanil consumption in the interventional group.

Conditions

Interventions

TypeNameDescription
DRUGOFA multimodal analgesiaMultimodal opioid free analgesia
DRUGStandard multimodal analgesiaStandard remifentanil analgesia

Timeline

Start date
2023-05-15
Primary completion
2026-05-15
Completion
2026-08-15
First posted
2023-04-24
Last updated
2025-05-28

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT05825560. Inclusion in this directory is not an endorsement.

Opioid-free Analgesia in Intensive Care Unit (NCT05825560) · Clinical Trials Directory